Asset
IZENCITINIB
Theravance Biopharma Inc. Ordinary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03635112 | phase2 | terminated | 2018-11-19 | 2021-12-30 | Theravance Biopharma | Efficacy and Safety of TD-1473 in Crohn's Disease |
| NCT03555617 | phase1 | completed | 2018-06-13 | 2018-07-15 | Theravance Biopharma | Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study |
| NCT03408470 | phase1 | completed | 2018-01-31 | 2018-02-21 | Theravance Biopharma | TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects |
| NCT02818686 | phase1 | completed | 2016-10-03 | 2018-03-29 | Theravance Biopharma | TD-1473 for Active Ulcerative Colitis (UC) |
FDA applications (0)
This company has no applications containing this asset.